- Home
- SMBC vs SVRA Comparison
SMBC vs SVRA Comparison
Compare SMBC & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SMBC
- SVRA
- Stock Information
- Founded
- SMBC 1887
- SVRA 2007
- Country
- SMBC United States
- SVRA United States
- Employees
- SMBC N/A
- SVRA N/A
- Industry
- SMBC Banks
- SVRA Biotechnology: Pharmaceutical Preparations
- Sector
- SMBC Finance
- SVRA Health Care
- Exchange
- SMBC Nasdaq
- SVRA Nasdaq
- Market Cap
- SMBC 648.4M
- SVRA 528.3M
- IPO Year
- SMBC N/A
- SVRA N/A
- Fundamental
- Price
- SMBC $51.70
- SVRA $2.38
- Analyst Decision
- SMBC Buy
- SVRA Buy
- Analyst Count
- SMBC 3
- SVRA 7
- Target Price
- SMBC $66.33
- SVRA $7.57
- AVG Volume (30 Days)
- SMBC 23.1K
- SVRA 2.6M
- Earning Date
- SMBC 07-28-2025
- SVRA 05-13-2025
- Dividend Yield
- SMBC 1.78%
- SVRA N/A
- EPS Growth
- SMBC 8.53
- SVRA N/A
- EPS
- SMBC 4.99
- SVRA N/A
- Revenue
- SMBC $172,928,000.00
- SVRA N/A
- Revenue This Year
- SMBC $15.31
- SVRA N/A
- Revenue Next Year
- SMBC $7.33
- SVRA N/A
- P/E Ratio
- SMBC $10.34
- SVRA N/A
- Revenue Growth
- SMBC 6.00
- SVRA N/A
- 52 Week Low
- SMBC $39.90
- SVRA $1.89
- 52 Week High
- SMBC $68.69
- SVRA $5.11
- Technical
- Relative Strength Index (RSI)
- SMBC 42.13
- SVRA 40.34
- Support Level
- SMBC $51.76
- SVRA $1.89
- Resistance Level
- SMBC $53.42
- SVRA $2.55
- Average True Range (ATR)
- SMBC 1.16
- SVRA 0.20
- MACD
- SMBC -0.32
- SVRA -0.04
- Stochastic Oscillator
- SMBC 11.76
- SVRA 37.40
About SMBC Southern Missouri Bancorp Inc.
Southern Missouri Bancorp Inc is a us-based holding company for Southern Missouri Savings Bank. The principal business of the bank consists of attracting retail deposits from the general public and using such deposits along with wholesale funding from the Federal Home Loan Bank of Des Moines, and to a lesser extent, brokered deposits, to invest in one- to four-family residential mortgage loans, mortgage loans secured by commercial real estate, commercial non-mortgage business loans, and consumer loans. It is engaged in providing the range of banking and financial services to individuals and corporate customers in its market areas. The company derives revenue principally from interest earned on loans, debt securities, bank card interchange fees, loan late charges and another fee income.
About SVRA Savara Inc.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.